Back to results
US 2021/0196744 A1Published application
Compositions for cancer therapy and methods
AssigneeAIM ImmunoTech Inc.
InventorsDavid R. STRAYER, Thomas K. EQUELS
Life of this patent
Estimating the term…
Abstract
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.
Claims11
A composition for treating cancer comprising:
- a checkpoint inhibitor and ATIE;
- wherein the ATIE is at least one selected from the group consisting of:
- rIn•ribo(C4U)n;
- rIn•ribo(C5U)n;
- rIn•ribo(C6U)n;
- rIn•ribo(C7U)n;
- rIn•ribo(C8U)n;
- rIn•ribo(C9U)n;
- rIn•ribo(C10U)n;
- rIn•ribo(C11U)n;
- rIn•ribo(C12U)n;
- rIn•ribo(C13U)n;
- rIn•ribo(C14U)n;
- rIn•ribo(C15U)n;
- rIn•ribo(C16U)n;
- rIn•ribo(C17U)n;
- rIn•ribo(C18U)n;
- rIn•ribo(C19U)n;
- rIn•ribo(C20U)n;
- rIn•ribo(C21U)n;
- rIn•ribo(C22U)n;
- rIn•ribo(C23U)n;
- rIn•ribo(C24U)n;
- rIn•ribo(C25U)n;
- rIn•ribo(C26U)n;
- rIn•ribo(C27U)n;
- rIn•ribo(C28U)n;
- rIn•ribo(C29U)n;
- rIn•ribo(C30U)n;
- rIn•ribo(C31U)n;
- rIn•ribo(C32U)n;
- rIn•ribo(C33U)n;
- rIn•ribo(C34U)n;
- rIn•ribo(C35U)n;
- rIn•r(Cp•23, G>p)n;
- rIn•ribo(C4-29U)n;
- rIn•r(C11-14U)n;
- rIn•ribo(C30-35U)n;
- rugged dsRNA;
- and r(Poly A•Poly U)n.
37 more elements
Dependencies are inferred from the claim text.